Moderna, Inc.
572 articles with Moderna, Inc.
-
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
5/19/2021
Halberd Corporation was featured in a recent MarketWatch article, "New Approaches to Covid-19 Treatment Enter the Picture," along with six other notable biotechnology companies.
-
COVID-19 News: Test for Asymptomatic People, Bemcentinib in Hospitalized COVID-19 Patients and More
5/18/2021
Please check out the biopharma industry's COVID-19 stories that are trending for May 18, 2021. -
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
-
A study, published recently in the New England Journal of Medicine, demonstrated no obvious safety signals among pregnant persons who received the mRNA vaccines.
-
Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine
5/12/2021
25 million doses includes 10 million doses of mRNA-1273 to begin delivery in 2021 and 15 million doses of updated variant booster candidate to begin delivery in 2022
-
New mutations of the SARS-CoV-2 virus are continuing to be discovered. As we’ve seen from the most common variants of the virus, infectiousness appears to be the trait most familiar to all of them.
-
The U.S. FDA expanded the Emergency Use Authorization for the Pfizer and BioNTech vaccine to include adolescents ages 12 to 15 after clinical data showed 100% efficacy response.
-
2021 COVID-19 News: India Variant a Global Concern, Low Risk of Serious Long Term Effects and More
5/11/2021
Please check out the biopharma industry's COVID-19 stories that are trending for May 11, 2021. -
Moderna to Present at the Bank of America 2021 Healthcare Conference
5/7/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that David Meline, Chief Financial Officer, and Lavina Talukdar, Senior Vice President & Head of Investor Relations, will participate in a fireside chat at the Bank of America 2021 Healthcare Conference on May 13th, 2021 at 11:00 a.m. ET.
-
On Thursday, Pfizer Chief Executive Officer Albert Bourla who is “not at all” in favor of the U.S. position, stated that the real challenge is manufacturing capacity.
-
Six months after receiving Emergency Use Authorization from the U.S. FDA for COVID-19 vaccines, Pfizer/BioNTech and Moderna are planning to seek full approval for the preventative medications.
-
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
-
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
-
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
5/6/2021
SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants
-
Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses
5/6/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a new supply agreement with the Swiss Federal Government for 7 million doses of booster vaccine in 2022, with an additional option for another 7 million doses for delivery during the second half of 2022 or first quarter of 2023.
-
Newly-published studies suggest currently authorized COVID-19 vaccines may be effective for protecting against new and emerging variants of the novel coronavirus, while booster doses of these vaccines may improve the overall efficiencies of these immunizations at combating these variants.
-
While the U.S. had been one of a few rich nations holding out – along with Canada, the European Union and Britain – on some level, Wednesday’s announcement of support for the proposal is not unexpected.
-
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
5/5/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern,
-
Moderna Announces Expansion of its Manufacturing Technology Center in Massachusetts
5/4/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an expansion of the Moderna Technology Center in Norwood, MA including more than doubling of space to transform the facility from a production and lab space to an industrial technology center.